▪ Affects ~31.9 million in the US 1 -11%-20% of children 2 -7% of adults 1 ▪ AD often the first sign of long-term disease continuum 3 -60% eventually develop asthma or allergic rhinitis -30% develop food allergies If not resolved in 7 days, consider nonadherence, misdiagnosis, contact allergy to prescription, referral *Indicated for patients at least 2 years old. †Indicated for patients at least 12 years old. ‡Not approved by FDA to treat AD. §Not recommended for long-term maintenance. 
Severe

Granted accelerated FDA approval March 2017 based on short-term results in SOLO 1 and SOLO 2 trials and long-term (52 weeks) results in CHRONOS AD LIBERTY trial.
Approved for adolescents 12-17 March 11, 2019. 
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Efficacy in Pruritus
Efficacy in QOL Improvements
Patients in phase 3 trials who demonstrated improvements in QOL (eg, sleep, anxiety, depression) as indicated by least squares* mean change in DLQI score
